Nephrology Doctors in Dover, DE Accepting Medicare

6 Nephrology doctors found. Showing 1 - 6

Gertrude Findley-christian, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-734-3227    Fax: 302-734-0391

Sangeetha Satyan, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-734-3227    Fax: 302-734-0391

Francis A Marro, M.D. Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 748 S New St, Suites C & D, Dover, DE 19904 Phone: 302-734-3227    Fax: 302-734-0391

Svastijaya Daviratanasilpa, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-424-3694    Fax: 302-424-3697

Daniel N Coar, MD Internal Medicine - Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-734-3227    Fax: 302-734-0391

G Jeffrey Milan, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1198 S Governors Ave Ste B100, Dover, DE 19904 Phone: 302-734-3227    Fax: 302-734-0391

News Archive

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

Three studies in acid maltase deficiency or Pompe's disease are progressing on schedule

Three studies in acid maltase deficiency (AMD, or Pompe's disease) being conducted by Genzyme of Cambridge, Mass., with support from MDA, are progressing on schedule, the company says.

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

Lawmaker cancels hearing on big corporations' tax deductions related to health reform

House Energy and Commerce Committee Chairman Henry Waxman, D-Calif., canceled a hearing set for next week that would have probed recent announcements by large firms that they are taking millions of dollars in health law-related write-downs, Kaiser Health News reports.

Tumour suppressor gene family may be key to new colon cancer drugs

In the hunt for new cancer drug targets, scientists from the Johns Hopkins Kimmel Cancer Center and the Howard Hughes Medical Institute have discovered mutations in a family of genes linked to more than a quarter of colon cancers, as well as several other common cancers including breast and lung.

Read more Medical News

› Verified 3 days ago